AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14663473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11042231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 2.5, 5, 7.5 or 10 mg twice daily
Number of subjects: 130
Study 11042231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 130
Study 8836161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vomeropherin pregna‐4,20‐diene‐3,6‐dione (PDD) at a concentration of 5 x 10(9) M delivered to the VNO
Number of subjects: 0
Study 8836161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vomeropherin pregna‐4,20‐diene‐3,6‐dione (PDD)
Number of subjects: 0
Study 8836161 — intervention group
Group type: COMPARATOR
Intervention: Identical stimuli delivered to nasal respiratory epithelium or olfactory epithelium
Number of subjects: 0
Study 1595823 — intervention group
Group type: EXPERIMENTAL
Intervention: Added-purpose task
Number of subjects: 30
Study 1595823 — intervention group
Group type: COMPARATOR
Intervention: Single-purpose task
Number of subjects: 30
Study 3883742 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 13
Study 3883742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31199210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 5 mg
Number of subjects: 0
Study 31199210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 0
Study 31199210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 15 mg
Number of subjects: 0
Study 31199210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 0
Study 31199210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31199210 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 0
Study 31199210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (after 52 weeks)
Number of subjects: 0
Study 29908336 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) with praise and financial incentives targeted at abstinence from opiates or attendance at treatment sessions
Number of subjects: 155000
Study 29908336 — intervention group
Group type: COMPARATOR
Intervention: No contingency management (CM)
Number of subjects: 155000
Study 27737664 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 60 mg
Number of subjects: 1015
Study 27737664 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg
Number of subjects: 1015
Study 27737664 — intervention group
Group type: COMPARATOR
Intervention: naproxen 1000 mg
Number of subjects: 1015
Study 27737664 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 60 mg (escalated to 90 mg)
Number of subjects: 1015
Study 27737664 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg (continued)
Number of subjects: 1015
Study 27737664 — intervention group
Group type: COMPARATOR
Intervention: naproxen 1000 mg (continued)
Number of subjects: 1015
Study 27737664 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 1015
Study 26034743 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop ergonomic training
Number of subjects: 503
Study 26034743 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet ergonomic training
Number of subjects: 503
Study 26034743 — intervention group
Group type: COMPARATOR
Intervention: Lecture ergonomic training
Number of subjects: 503
Study 23622007 — intervention group
Group type: EXPERIMENTAL
Intervention: Aeroneb (MMAD, 5 μm)
Number of subjects: 8
Study 23622007 — intervention group
Group type: EXPERIMENTAL
Intervention: Aeroneb (MMAD, 3.0 μm)
Number of subjects: 8
Study 23622007 — intervention group
Group type: EXPERIMENTAL
Intervention: Wright nebulizer (MMAD, 1.0 μm)
Number of subjects: 8
Study 23622007 — intervention group
Group type: COMPARATOR
Intervention: Comparison across all particle sizes
Number of subjects: 8
Study 20525995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 519
Study 20525995 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 519
Study 18391266 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual patient system
Number of subjects: 23
Study 16791612 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hydrocortisone (HC)
Number of subjects: 78
Study 16791612 — intervention group
Group type: COMPARATOR
Intervention: Control (Vaseline)
Number of subjects: 78
Study 16791612 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hydrocortisone (HC) with physiotherapy (PT)
Number of subjects: 78
Study 16791612 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with retractile prepuces
Number of subjects: 78
Study 16791612 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with nonretractile prepuces
Number of subjects: 78
Study 12659547 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (pharmacotherapy and psychodynamic supportive psychotherapy)
Number of subjects: 72
Study 12659547 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 72
Study 11069573 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol powder
Number of subjects: 30
Study 11069573 — intervention group
Group type: COMPARATOR
Intervention: Sham provocation
Number of subjects: 30
Study 9189727 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (NORM) for 3 days, 426 (137) g.day‐1 CHO [5.9 (1.4) g.kg‐1 body mass (BM)]
Number of subjects: 6
Study 9189727 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional carbohydrate (SUPP) for 3 days, 661 (76) g.day‐1 CHO [9.3 (0.7) g.kg‐1 BM]
Number of subjects: 6
Study 9189727 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (NORM)
Number of subjects: 6
Study 9189727 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional carbohydrate (SUPP)
Number of subjects: 6
Study 1556286 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based social competence training (20-session program)
Number of subjects: 282
Study 3104123 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal Therapeutic System releasing 10 mg of nitroglycerin over 24 hours (TTS 10)
Number of subjects: 10
Study 3104123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual isosorbide dinitrate 5 mg (ISDN)
Number of subjects: 10
Study 3104123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30951193 — intervention group
Group type: EXPERIMENTAL
Intervention: axitinib plus dalantercept
Number of subjects: 124
Study 30951193 — intervention group
Group type: COMPARATOR
Intervention: placebo plus axitinib
Number of subjects: 124
Study 26122982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package delivered by community midwives including psychoeducation, problem solving treatment, and parenting skills, with clinical support via mobile phone.
Number of subjects: 686
Study 26122982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package delivered by community midwives.
Number of subjects: 686
Study 26122982 — intervention group
Group type: COMPARATOR
Intervention: Care as usual enhanced by further training of providers in recognition and standard treatment of depression.
Number of subjects: 686
Study 23541458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8122
Study 23541458 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 8122
Study 20512335 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GJ) consumed 200 mL three times a day for three days prior to PK analysis.
Number of subjects: 8
Study 20512335 — intervention group
Group type: COMPARATOR
Intervention: Midazolam as a phenotypic probe for CYP3A4 activity.
Number of subjects: 8
Study 19751620 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetrators of IPV (Perps)
Number of subjects: 236
Study 16919213 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 43
Study 16919213 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses and night splints
Number of subjects: 43
Study 16919213 — intervention group
Group type: COMPARATOR
Intervention: Night splints alone
Number of subjects: 43
Study 14767810 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4 -589-C/T polymorphism
Number of subjects: 1043
Study 11729382 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 541
Study 11729382 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation
Number of subjects: 541
Study 11729382 — intervention group
Group type: COMPARATOR
Intervention: R1 resection margin status
Number of subjects: 541
Study 9044491 — intervention group
Group type: EXPERIMENTAL
Intervention: Open palm technique
Number of subjects: 45
Study 9044491 — intervention group
Group type: COMPARATOR
Intervention: Single resuscitator technique
Number of subjects: 45
Study 9044491 — intervention group
Group type: EXPERIMENTAL
Intervention: Two resuscitators technique
Number of subjects: 45
Study 7910880 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular salbutamol (2 puffs - 200 micrograms - four times daily)
Number of subjects: 341
Study 2853163 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate Hydroxylapatite (20 mesh)
Number of subjects: 0
Study 2853163 — intervention group
Group type: COMPARATOR
Intervention: Cone form Hydroxylapatite
Number of subjects: 0
Study 30149444 — intervention group
Group type: COMPARATOR
Intervention: Nostalgia (Experiment 1)
Number of subjects: 106
Study 30149444 — intervention group
Group type: COMPARATOR
Intervention: Nostalgia induced by music (Experiment 2)
Number of subjects: 106
Study 30149444 — intervention group
Group type: COMPARATOR
Intervention: Nostalgia (Experiment 3)
Number of subjects: 106
Study 26292692 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-movement neuromuscular electrical stimulation
Number of subjects: 72
Study 26292692 — intervention group
Group type: COMPARATOR
Intervention: Control, sensory threshold-neuromuscular electrical stimulation, and motor threshold-neuromuscular electrical stimulation
Number of subjects: 72
Study 24720396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligature-less brackets with ß-titanium reverse-curve wires (0.017 x 0.025 inch)
Number of subjects: 20
Study 24720396 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets with Elgiloy multiloop wires (0.016 x 0.022 inch)
Number of subjects: 20
Study 23926329 — intervention group
Group type: EXPERIMENTAL
Intervention: AAQ + PQ
Number of subjects: 331
Study 23926329 — intervention group
Group type: EXPERIMENTAL
Intervention: DHP + PQ
Number of subjects: 331
Study 20193095 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (10 microg daily)
Number of subjects: 200
Study 20193095 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (10 microg daily) + Calcium (600 mg daily)
Number of subjects: 200
Study 20193095 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (including 10 microg Vitamin D) + Calcium (600 mg daily)
Number of subjects: 200
Study 20193095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 18641816 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocurve contact lenses
Number of subjects: 126
Study 18641816 — intervention group
Group type: COMPARATOR
Intervention: Bicurve Soper-McGuire design contact lenses
Number of subjects: 126
Study 16511419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular telephone intervention (8 counseling sessions plus usual care)
Number of subjects: 95
Study 16511419 — intervention group
Group type: COMPARATOR
Intervention: Usual care (brief physician advice, self-help materials, nicotine replacement therapy)
Number of subjects: 95
Study 16511419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular telephone intervention
Number of subjects: 95
Study 14570667 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture (2‐mA constant current, 1 Hz monophasic)
Number of subjects: 21
Study 14570667 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual auricular acupuncture (no electrical stimulation)
Number of subjects: 21
Study 11011651 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Talk - disease-specific monitoring system with automated questions
Number of subjects: 0
Study 11011651 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Talk - age-specific automated health screens
Number of subjects: 0
Study 8838965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin (5 g loading dose, intravenous infusion twice, 4 h apart)
Number of subjects: 102
Study 8838965 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous infusion)
Number of subjects: 102
Study 1426389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) after ovarian stimulation with human menopausal gonadotropin (hMG)
Number of subjects: 84
Study 6342752 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary radiation therapy
Number of subjects: 0
Study 6342752 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 0
Study 29608125 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiologic tape (KT) applied to spinal nerves T10‐L1 and S2‐S4
Number of subjects: 60
Study 29608125 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with tape applied to spinal nerves T1‐T4
Number of subjects: 60
Study 29608125 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study 30446421 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal interventions tailored to individual patients
Number of subjects: 0
Study 25496083 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser (LLLT)
Number of subjects: 7
Study 25496083 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser (Placebo)
Number of subjects: 7
Study 18983869 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular and binocular slant cues
Number of subjects: 0
Study 15122953 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular nicotine brand
Number of subjects: 0
Study 15122953 — intervention group
Group type: COMPARATOR
Intervention: Low nicotine brand
Number of subjects: 0
Study 15122953 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions told regular nicotine
Number of subjects: 0
Study 15122953 — intervention group
Group type: COMPARATOR
Intervention: Instructions told low nicotine
Number of subjects: 0
Study 15122953 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nicotine (placebo effect)
Number of subjects: 0
Study 15122953 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular nicotine
Number of subjects: 0
Study 11181093 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (specific techniques not detailed)
Number of subjects: 0
Study 9748717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 100 mg capsule (Cefzon)
Number of subjects: 12
Study 9748717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 100 mg daily for 3 to 8 days
Number of subjects: 12
Study 9748717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 200 mg (2 capsules) daily for 4 to 14 consecutive days
Number of subjects: 12
Study 9748717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 12
Study 8164860 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ankle mobilization (elastic wrap or air-stirrup)
Number of subjects: 64
Study 8164860 — intervention group
Group type: COMPARATOR
Intervention: Elastic wrap
Number of subjects: 64
Study 2971515 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol, 5 mg mixed with ipratropium bromide 500 micrograms
Number of subjects: 40
Study 2971515 — intervention group
Group type: COMPARATOR
Intervention: salbutamol, 5 mg
Number of subjects: 40
Study 12402423 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 0
Study 12402423 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IL-2 and IFN-alpha
Number of subjects: 0
Study 12402423 — intervention group
Group type: COMPARATOR
Intervention: Addition of other cytokines (e.g., GM-CSF) or chemotherapy
Number of subjects: 0
Study 30841688 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrett calculator
Number of subjects: 64
Study 30841688 — intervention group
Group type: COMPARATOR
Intervention: AcrySof calculator
Number of subjects: 64
Study 29656500 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) for six months
Number of subjects: 0
Study 29656500 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST) for six months
Number of subjects: 0
Study 29656500 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined three-month ST+TRT
Number of subjects: 0
Study 29656500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26409243 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Marrow (BM) graft
Number of subjects: 499
Study 26409243 — intervention group
Group type: COMPARATOR
Intervention: Peripheral Blood Stem Cells (PBSC) graft
Number of subjects: 499
Study 24832980 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 37
Study 24832980 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 37
Study 24832980 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 37
Study 21638162 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquamid® filler, 8 ml per session, retreated every 8 weeks until full correction observed.
Number of subjects: 31
Study 21638162 — intervention group
Group type: COMPARATOR
Intervention: Aquamid® filler, 2 ml per session, retreated every 8 weeks until full correction observed.
Number of subjects: 31
Study 19553067 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive continuing care
Number of subjects: 342
Study 19553067 — intervention group
Group type: COMPARATOR
Intervention: Standard continuing care
Number of subjects: 342
Study 18813866 — intervention group
Group type: COMPARATOR
Intervention: 600 mg of Shoyu polysaccharides (SPS) daily for 2 weeks
Number of subjects: 20
Study 18813866 — intervention group
Group type: COMPARATOR
Intervention: 600 mg of Shoyu polysaccharides (SPS) daily for 4 weeks
Number of subjects: 20
Study 15755232 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively personalized booklet
Number of subjects: 240
Study 15755232 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally personalized booklet
Number of subjects: 240
Study 15755232 — intervention group
Group type: COMPARATOR
Intervention: Standard booklet
Number of subjects: 240
Study 12464889 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary distraction osteogenesis
Number of subjects: 18
Study 12464889 — intervention group
Group type: COMPARATOR
Intervention: Conventional maxillary advancement
Number of subjects: 18
Study 10622347 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 800 mg
Number of subjects: 228
Study 10622347 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 8 mg
Number of subjects: 228
Study 7594026 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbutamine
Number of subjects: 210
Study 7594026 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 210
Study 1952008 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate ointment
Number of subjects: 104
Study 1952008 — intervention group
Group type: COMPARATOR
Intervention: Eutectic mixture of local anaesthetics cream
Number of subjects: 104
Study 6764162 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate
Number of subjects: 17
Study 6764162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31687933 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel paclitaxel-coated drug-coated balloon (DCB)
Number of subjects: 171
Study 31687933 — intervention group
Group type: COMPARATOR
Intervention: Uncoated plain old balloon angioplasty (POBA)
Number of subjects: 171
Study 30850310 — intervention group
Group type: EXPERIMENTAL
Intervention: It's Your Game…Keep It Real program
Number of subjects: 1693
Study 29855986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (120 mg, twice a day)
Number of subjects: 197
Study 29855986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 197
Study 29855986 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline
Number of subjects: 197
Study 26498455 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseload midwifery
Number of subjects: 2314
Study 26498455 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2314
Study 24794703 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analogues (detemir and aspart)
Number of subjects: 141
Study 24794703 — intervention group
Group type: COMPARATOR
Intervention: Human insulin (human neutral protamine Hagedorn and human regular)
Number of subjects: 141
Study 22045363 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (alpha agonist)
Number of subjects: 137
Study 22045363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 19551459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-[(13)C]ureide breath test (LUBT) with 2 g of lactose-[(13)C]ureide
Number of subjects: 22
Study 19551459 — intervention group
Group type: COMPARATOR
Intervention: Glucose hydrogen breath test (GHBT) with 50 g glucose
Number of subjects: 22
Study 17461529 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynoplus (black cohosh and St. John's wort)
Number of subjects: 89
Study 17461529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 14604623 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication strategies developed to assist doctors in seeking informed consent to cancer clinical trials.
Number of subjects: 26
Study 14604623 — intervention group
Group type: EXPERIMENTAL
Intervention: Training package based on developed communication strategies.
Number of subjects: 26
Study 12884566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) program
Number of subjects: 27
Study 9523208 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0
Study 9523208 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 0
Study 9523208 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM
Number of subjects: 0
Study 8602384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotoxic chemotherapy
Number of subjects: 77